Patent intelligence · AU
AU 2024342196
NOVEL ECTEINASCIDIN DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF
NOVEL ECTEINASCIDIN DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF
Patent details — AU 2024342196
- Jurisdiction
- AU
- Status
- granted
- Grant date
- Apr 2, 2026
- Expiration
- Mar 28, 2046
- Applicant
- ABBVIE GROUP HOLDINGS LTD [BM]
- CPC classes
- A61K 31/ 4995 A I, A61K/314995, A61K/4764, A61K/4768
Quick answer
AU 2024342196 (NOVEL ECTEINASCIDIN DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF) is held by ABBVIE GROUP HOLDINGS LTD [BM]. Status: granted. Granted Apr 2, 2026. Expires Mar 28, 2046 (20 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ABBVIE GROUP HOLDINGS LTD [BM]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 4995 A I, A61K/314995, A61K/4764, A61K/4768, A61K/476803, A61P/3500
More from ABBVIE GROUP HOLDINGS LTD [BM]
Related pharmaceutical patents in our USPTO index.
-
WO 2026039538
MÉTHODES DE TRAITEMENT DE TUMEURS PANCRÉATIQUES EXPRIMANT CERTAINS BIOMARQUEURS
granted -
US 20260035439
Anti-Sars-COV-2 Antibodies and Uses Thereof
granted -
EP 4670742
ANTI-CD79B-ANTIKÖRPER-WIRKSTOFFKONJUGATE
granted -
AU 2024276234
METHODS OF TREATMENT USING ANTI-C-MET ANTIBODY DRUG CONJUGATES
granted -
WO 2025230528
MÉTHODES DE TRAITEMENT DE LA SCLÉROSE LATÉRALE AMYOTROPHIQUE
granted -
US 2025333394
Tiparp Inhibitor Compounds
granted -
EP 4640274
LPAR1-INHIBITOREN
granted
Frequently asked questions
What is US patent 2024342196?
AU 2024342196 (NOVEL ECTEINASCIDIN DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF) is held by ABBVIE GROUP HOLDINGS LTD [BM]. Status: granted. Granted Apr 2, 2026. Expires Mar 28, 2046 (20 years remaining) — relevant for patent-cliff and LOE planning.
Who owns AU 2024342196?
ABBVIE GROUP HOLDINGS LTD [BM] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does AU 2024342196 expire?
Our index shows an expiration date of Mar 28, 2046 (20 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.